Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibonta versus Dysport for correction of glabellar lines
IRCT20150101020514N32Phase 3Completed
- Sponsor
- Zist Daru Danesh
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (2 arms), sponsored by Zist Daru Danesh. Primary endpoint: Percentage of subjects with improvement in glabellar lines at maximum frown. Started Dec 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on IRCT20150101020514N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150101020514N32.